Publications in VIVO

Co-author Network

Co-investigator Network

Anna Parks, MD

Person

Positions

Assistant Professor, University of Utah, Division of Hematology
Fellow (specialty or subspecialty), University of California, San Francisco

Location

Salt Lake City, UT

I am a physician investigator applying aging research methods to improve the care of older adults with non-malignant hematologic disease. I am an Assistant Professor and Director of Thrombosis in the Division of Hematology & Hematologic Malignancies and a Center on Aging faculty member at the University of Utah.

My goal is to establish cross-disciplinary networks as a hematology collaborator within geriatrics and a geriatrics collaborator within hematology to improve outcomes for older adults with venous thromboembolism and other blood diseases. To that end, my work spans the translational science spectrum, using collaborations with basic scientists, qualitative methods, powerful observational datasets, and partnerships with patient advocacy organizations. We focus both on traditional outcomes (e.g., major bleeding and mortality) and aging-centered outcomes (e.g., frailty and functional independence).

Clinical Disciplines

Beeson awardee GEMSSTAR awardee

Publications
Research
Other
View All

Selected Publications

article
1. An international survey of clinician recommendations for physical activity after venous thromboembolism.. Thrombosis research. -. 2025
2. Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers.. Alzheimer's & dementia (New York, N. Y.). 11:-. 2025
3. Patient-centered management of heavy menstrual bleeding while on anticoagulation: A survey study.. European journal of obstetrics, gynecology, and reproductive biology. -. 2025
4. The clot cases conference: a proposed model to enhance multidisciplinary thrombosis care.. Journal of thrombosis and thrombolysis. 2025
5. A qualitative study of people with Alzheimer's disease in a memory clinic considering lecanemab treatment.. Journal of Alzheimer's disease : JAD. 105:494-504. 2025
6. Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review.. JAMA internal medicine. 185:450-456. 2025
7. Platelet response following dexamethasone in obese vs nonobese patients with primary, acute immune-mediated thrombocytopenia.. Research and practice in thrombosis and haemostasis. 9:-. 2025
8. "I'm worth saving"- A Qualitative Study of People with Alzheimer's Disease Considering Lecanemab Treatment.. medRxiv : the preprint server for health sciences. 2025
9. Functional disability after clinically significant extracranial bleeding: a secondary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) Trial.. Journal of thrombosis and haemostasis : JTH. 23:1507-1515. 2025
10. The impact of anticoagulant-related bleeding on quality of life: Development of a novel measure based on perspectives from older adults.. PloS one. 20:-. 2025
11. Anticoagulation at the end of life: whether, when, and how to treat.. Hematology. American Society of Hematology. Education Program. 2024:348-354. 2024
12. Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study.. Therapeutic advances in medical oncology. -. 2024
13. A sobering reminder and call to action: Preventing inpatient deaths from pulmonary emboli with a wraparound strategy.. Journal of hospital medicine. 20:422-423. 2024
14. Management of atrial fibrillation in older adults.. BMJ (Clinical research ed.). -. 2024
15. Anticoagulant therapy in renal insufficiency theme: Anticoagulation in complex situations.. Thrombosis research. -. 2024
16. NSAIDs and hormonal contraceptives are linked to VTE in women with no previous thrombotic disease.. Annals of internal medicine. 176:-. 2023
17. In intermediate- or high-risk PE, catheter-directed thrombolysis is linked to reduced mortality vs. systemic thrombolysis or anticoagulation.. Annals of internal medicine. 176:-. 2023
18. Excluding pregnancy-associated deep vein thrombosis with whole-leg ultrasound.. Research and practice in thrombosis and haemostasis. 7:-. 2023
19. Use of patient-reported outcome measures in patients with venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.. Journal of thrombosis and haemostasis : JTH. 21:2953-2962. 2023
20. Blood Clots, or Thrombosis, in Patients With Cancer.. JAMA oncology. 9:-. 2023
21. Periprocedural Anticoagulation.. Annals of internal medicine. 176:ITC49-ITC64. 2023
22. Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19.. JAMA network open. 6:-. 2023
23. Teaching a Deeper Understanding of the Medical Literature.. Journal of general internal medicine. 38:1059-1060. 2022
24. Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism.. Thrombosis research. 97-102. 2022
25. What Can At-home Genetic Tests Tell Me About My Health?. JAMA internal medicine. 182:-. 2022
26. Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: Practice patterns and outcomes at 33 hospitals.. PloS one. 17:-. 2022
27. Long-term functional outcomes and mortality after hospitalization for extracranial hemorrhage.. Journal of hospital medicine. 17:235-242. 2022
28. Persistent Gender Pay Gaps in Medicine: What Is Good for the Goose Is Better for the Gander's Paycheck.. JAMA internal medicine. 181:-. 2021
29. Anticoagulation at the End of Life: Time for a Rational Framework.. JAMA internal medicine. 181:-. 2021
30. An Elusive Seizure.. The Neurohospitalist. 12:188-194. 2021
31. Long-term individual and population functional outcomes in older adults with atrial fibrillation.. Journal of the American Geriatrics Society. 69:1570-1578. 2021
32. Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma.. Leukemia & lymphoma. 62:1003-1006. 2020
33. Long-term individual and population functional outcomes in older adults with atrial fibrillation.. medRxiv : the preprint server for health sciences. 2020
34. Succeeding in Aging Research During the Pandemic: Strategies for Fellows and Junior Faculty.. Journal of the American Geriatrics Society. 69:8-11. 2020
35. COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic.. Thrombosis research. 355-358. 2020
36. Refining Risk for Deep Vein Thrombosis in Hospitalized Patients.. Journal of general internal medicine. 33:-. 2018
37. Dabigatran Compared With Rivaroxaban vs Warfarin-Reply.. JAMA internal medicine. 177:-. 2017
38. Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding.. Seminars in thrombosis and hemostasis. 43:514-524. 2017
39. Applying Academic Detailing and Process Change to Promote Choosing Wisely-Reply.. JAMA internal medicine. 177:-. 2017
40. Women in Medicine and Patient Outcomes: Equal Rights for Better Work?. JAMA internal medicine. 177:-. 2017
41. Comparing Non-Vitamin K Oral Anticoagulants: Where We Are Now.. JAMA internal medicine. 176:-. 2016
42. From Choosing Wisely to Practicing Value-More to the Story.. JAMA internal medicine. 176:1571-1572. 2016
43. Anticoagulation in the Very Old.. JAMA internal medicine. 176:-. 2016
44. Anticoagulation in Older Adults with Multimorbidity.. Clinics in geriatric medicine. 32:331-46. 2016
45. Teaching High-Value Care on Rounds: Modeling Moderation.. JAMA internal medicine. 176:262-3. 2016
46. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?. Journal of gastrointestinal cancer. 46:161-5. 2015
47. Male obesity and alteration in sperm parameters.. Fertility and sterility. 90:2222-5. 2008